Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Paper of the day - Early interferon 'prevents development of disability'

Early treatment of multiple sclerosis with interferon prevents the development of confirmed disability, the follow up results of a randomised controlled trial suggest.

Three years after initial randomisation to interferon or placebo, early treatment with interferon, given to patients with a clinical event suggestive of the first stages of MS, was found to reduce the risk of clinically definite multiple sclerosis by 41% compared with initial placebo and then delayed treatment.

In the follow up analysis of the BENEFIT study 392 patients were followed up for three years, and 99 (37%) of the patients who received early interferon developed MS compared to 85 (51%) of those who did not receive interferon until later (when they developed MS, or at the end of the two-year trial). The absolute risk reduction for development of MS was 14%.

Over the three years of follow up, 42 (16%) of the patients in the early treatment group and 40 (24%) in the delayed treatment group had confirmed progression of disability, a significant risk reduction of 40% (absolute risk reduction 8%).

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say